Skip to content

DBV Technologies DBVT Debt-to-equity

Debt-to-equity at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
0.0×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
0.0×
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
0.0×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
0.1×-7.2×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
0.1×-0.1×
Alumis Inc. logo
Alumis Inc.ALMS
0.1×+0.1×

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$923.31M+259%
Enterprise value$700.21M+179%
P/S159.6×+87.1×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Current ratio4.8×+4.0×

Where this comes from

Calculated from DBV Technologies’s reported figures.

Based on the most recent quarter.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's debt-to-equity?
DBV Technologies (DBVT) reported debt-to-equity of 0× in Q1 2026.
How has DBV Technologies's debt-to-equity changed year-over-year?
DBV Technologies's debt-to-equity decreased by 98.8% year-over-year, from 2.5× to 0×.
What is the long-term trend for DBV Technologies's debt-to-equity?
Over 5 years (2020 to 2025), DBV Technologies's debt-to-equity has grown at a -11.0% compound annual growth rate (CAGR), from 0.1× to 0×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.